Victoria Johnson

Refardt discussed findings from the largest hyponatremia trial ever conducted, including 2174 participants across 9 European centers.

The dapagliflozin group had an average eGFR rate of -2.24 mL/min/1.73 m2 compared to -3.67 mL/min/1.73 m2 in the control group after about 1.5 years of follow-up.

Participants receiving semaglutide had an overall hazard ratio of 0.76 in the composite primary outcome of kidney failure, serious eGFR decline, or death compared to placebo.

Herrington shared the carryover effects observed in the post-trial follow-up of the phase 3 EMPA-KIDNEY trial.

Yee discussed how the data show a benefit in this hard-to-treat population, which was not seen in the heterogeneous FSGS group.

Zand discussed interim 12-month findings from an open-label, phase 2 trial currently ongoing for patients with refractory primary focal segmental glomerulosclerosis.

After discontinuing therapy, treated participants still had an overall 13% reduction in the risk of kidney disease progression or cardiovascular death.

Overall, 8 of 20 patients had complete or partial remission of their FSGS.

The data, which will be presented at a later time, may enable regulatory submission for accelerated approval to the FDA.

Patients exposed to screening were also more likely to receive vaccinations and consult a cardiologist and/or a pneumologist.

Masri previewed data to be presented at the AHA 2024 Scientific Sessions and shared his excitement for the ongoing phase 3 trial of NTLA-2001.

Ustekinumab-aekn is set to enter the US market no later than February 21, 2025, as per a settlement and license agreement between Janssen, Teva, and Alvotech.

Investigators analyzed antibody response after 2 SARS-CoV-2 vaccinations.

Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.

The treatment did seem to blunt the glycemic response and influence some inflammatory cytokines.

The ER fluticasone propionate intra-articular injection significantly reduced pain compared with control for up to 14 weeks.

The study also identified a tendency for more prevalent human herpesvirus 6B in people with FM than in those without.

Adherence to a preventative, favorable lifestyle significantly reduced CVD risk in participants with high and low genetic risk.

Findings from the study also continued to support a positive Ara h 2-sIgE as the single most important predictor of peanut allergy.

Two pivotal phase 3 studies previously met their endpoints of significantly reducting daily pain compared with placebo.

Compared with older nomenclature, MASLD was significantly associated with severe artery calcification.

The burden of LC-MASLD has significantly increased, especially in economically disadvantaged countries.

The new administration options allow a single-injection option for patients that require a 320 mg dose.

Of patients randomized to guselkumab Q8W, 93% to 99% maintained minimally clinically important improvements in joint disease through 1 year.

Over 70% of participants with MSK pain after COVID-19 fulfilled ACR fibromyalgia criteria in new research.

Calabrese discussed considerations for patients with rheumatic disease diagnosed with COVID-19 and the virus’s role in promoting inflammation.

The anti-TFPI significantly reduced ABR compared to routine prophylaxis treatment in the phase 3 BASIS trial.

Second-generation long-acting injectables were particularly underutilized, and especially among older patients.

Being female and having bipolar II disorder were independent risk factors for serious AEs in a new study.

A comprehensive model of clinical and radiomic features was more accurate in distinguishing flares than either model alone.